TRVITrevi Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Trevi Therapeutics, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TRVIEsta | $2.2B#8 | — | 6.7x#9 | — | — | 10.7%#6 | — | -13.3%#3 | — | — | 89.8%#1 | — |
| VERA | $2.4B#1 | — | 5.9x#8 | — | — | -96.9%#11 | — | -73.5%#11 | -72.7%#4 | — | 36.8%#4 | — |
| NKTR | $2.3B#2 | — | 2.6x#4 | 42.2x#7 | -43.9%#10 | -37.8%#9 | -253.7%#6 | -18.2%#4 | -14.0%#3 | — | 33.6%#5 | — |
| SLS | $2.3B#3 | — | 16.9x#13 | — | -100.0%#11 | 13.0%#4 | — | -19.5%#6 | — | — | — | — |
| OCUL | $2.2B#5 | — | 4.3x#5 | 43.0x#8 | -18.5%#9 | -37.4%#8 | -519.8%#8 | -51.1%#10 | — | — | — | — |
| PVLA | $2.2B#4 | — | 10.3x#12 | 52.3x#9 | 65.3%#3 | -139.3%#12 | -90.2%#5 | -19.2%#5 | — | — | — | — |
| PBH | $2.2B#6 | 12.9x#1 | 1.1x#1 | 2.0x#3 | -4.3%#8 | -11.3%#7 | 28.4%#1 | 9.9%#1 | 5.9%#1 | 4#1 | — | — |
| GENB | $2.2B#7 | — | 4.8x#7 | — | — | — | — | 0.0%#2 | — | — | — | — |
| NUVB | $2.2B#10 | — | 8.5x#10 | 34.2x#5 | 699.0%#1 | 64.0%#2 | -338.7%#7 | -80.6%#12 | -87.4%#6 | — | 86.7%#2 | — |
| SRPT | $2.2B#9 | — | 1.4x#2 | 1.2x#2 | 4.3%#7 | -403.3%#15 | -37.5%#3 | -46.7%#9 | -73.0%#5 | — | 19.5%#6 | — |
| BHC | $2.1B#11 | — | — | 0.2x#1 | 6.7%#6 | 441.3%#1 | 17.7%#2 | — | 3.6%#2 | — | — | 16.6%#1 |
| ZBIO | $2.1B#12 | — | 8.5x#11 | 210.2x#10 | 100.0%#2 | -140.6%#13 | -3830.6%#10 | -152.9%#14 | -296.6%#7 | — | 68.8%#3 | — |
| BHVN | $2.0B#13 | — | 165.5x#15 | — | — | 12.7%#5 | — | -6045.0%#15 | — | — | — | — |
| AGIO | $2.0B#14 | — | 2.0x#3 | 37.3x#6 | 48.0%#4 | -161.3%#14 | -873.9%#9 | -40.3%#8 | — | — | — | — |
| RAPP | $2.0B#15 | — | 4.7x#6 | — | — | -42.4%#10 | — | -26.4%#7 | — | — | — | — |
| ZYME | $2.0B#16 | — | 24.5x#14 | 18.5x#4 | 38.9%#5 | 33.9%#3 | -87.3%#4 | -100.9%#13 | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice